Polaryx receives FDA’s IND approval for clinical trials of JNCL/CLN3
Category: #healthcare  By Akshay Kedari  Date: 2020-04-09
  • share
  • Twitter
  • Facebook
  • LinkedIn

Polaryx receives FDA’s IND approval for clinical trials of JNCL/CLN3

Polaryx Therapeutics, Inc., a developer of drug candidates for lysosomal storage disorders, has recently gained IND (Investigational New Drug Application) approval from the U.S. FDA. This approval is related to the study of PLX-200 treatment among patients suffering from JNCL or CLN3 (Juvenile Neuronal Ceroid Lipofuscinosis).

Juvenile Neuronal Ceroid Lipofuscinosis is a genetic lysosomal storage disorder that is caused by the mutation of the CLN3 gene. This kind of rare and fatal NCL disease is most prevalent and occurs among 3 out of 100,000 births. Patients with CLN3 suffer from several impairments including blindness, progressive neurological deterioration, seizures, severe motor & cognitive decline, eventually leading to death in the 2nd decade of life. No drugs are currently available to treat or delay the progress of this disease.

According to Dr. Hahn-Jun Lee, M.Sc., Ph.D., Chief Executive Officer and President of Polaryx Therapeutics, the company is excited at gaining approval from the FDA to carry out the clinical trials of the CLN3 with PLX-200. In addition to the latest FDA approval, it has also recently gained CLN2 IND approval with the PLX-200 drug. Its team of experts has been working continuously to accelerate the preparation of clinical trials and rapidly initiate the clinical studies.

As per the statement made by Alex Yang, J.D., LLM, Chief Executive Officer and President of Mstone Partners in Hong Kong & Polaryx Therapeutics’ Chair of the Board, the recent FDA approvals for CLN3 clinical trials with PLX-200 will enable the company to advance forward in conducting the clinical studies for human efficacy on a wide range of the Batten disease indications. The company is also planning to enter potential partnerships to expand its reach in other areas of lysosomal storage disorder and effectively discover potential treatment of this rare disease and cater to the unmet needs in the healthcare setting.

Source credit:

https://www.ptcommunity.com/wire/polaryx-therapeutics-receives-ind-approval-fda-study-plx-200-treatment-patients-juvenile

About Author

Akshay Kedari    

Akshay Kedari

Akshay holds a Bachelor’s degree in computer engineering. Despite having a penchant for software development and the like, Akshay took to writing as a career owing to his passion for the field. Presently, Akshay writes articles for itresearchbrief.com and a few oth...

Read More>>

More News By Akshay Kedari

Oscar Parodi becomes 1st UK infant to be treated with a Cannabis drug
Oscar Parodi becomes 1st UK infant to be treated with a Cannabis drug
By Akshay Kedari

The cannabis based drug has previously been used for epilepsy treatment and this study is being co...

Outcomes of dog cancer clinical trial increase hopes for human use
Outcomes of dog cancer clinical trial increase hopes for human use
By Akshay Kedari

Selvax Pty Ltd, the Australian cancer immunology group engaged in developing immunology based treatm...

KYB inks deal with REE Automotive to bring advanced EV solutions
KYB inks deal with REE Automotive to bring advanced EV solutions
By Akshay Kedari

  KYB’s highly advanced semi-active and active system solutions will drive the next-ge...